Yes Bank Share Price Target 2024, 2025, 2026, 2027, 2028, 2029, 2030 Fundamentals & Quarterly Results – Wockhardt is a worldwide pharmaceutical and biotechnology company that produces disposable dosage forms, injectable drugs, biopharmaceutical drugs, oral drugs, topically administered medications(ointments or creams). Wockhardt Pharma Limited is an Indian healthcare and pharmaceutical company that was started in 1967.Multinational enterprise has a presence in 30 countries all over the world and on all continents.
Latest Update – In the quarter that finished on 30th June 2024, Wockhardt announced on 9th August that their net loss had been reduced to Rs 16 crores from Rs 136 crores during the same period last year.
Wockhardt Overview
Contents
WOCKPHARMA began more than 5 decades ago. Since that time we have been in the forefront of the business’s evolution; a path that has been characterized by development and establishment of itself as an international leader in the sector. In fact, it is this global reach which generates about 67-percent of annual income.
| Company Name | Wockhardt |
| Listed at | NSE & BSE |
| Head Office | D-4 MIDC, Chikalthana Aurangabad, 431006, India |
| Board Of Directors |
|
| Official Website | wockhardt.com |
Latest Update – As compared to Rs. 136 crore in the year ago period, Wockhardt on August 9 stated that its net loss has decreased to Rs. 16 crore for the quarter that ended June 30, 2024.
Also Check Yes Bank Share Price Target
Wockhardt Business Profile
The firm is one of the three major Indian generic companies in UK and the sixth largest supplier of generics in Ireland, present in both Retail and Hospital channels. Its Wepox mark is the bioequivalent of Erythropoetin (market share of 21%) and Methylcobalamin trademark is number 1 with (Methycobal share 26.7%).
Also Check Tata Elxsi Share Price Target
Global Presence
India, USA, UK, Ireland and France are fully operational for the Co. Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Nepal, Uganda, Mauritius, Myanmar, Sri Lanka, Lebanon & Kuwait are some of the emerging markets where it markets some other products.
Also Check RBL Bank Share Price Target
Vaccine Manufacturing
A deal was struck between the UK Government and The Co. in order to fill and finish COVID-19 vaccines that were manufactured at CP Pharmaceuticals; a subsidiary company belonging to Wockhardt which hails from Wrexham, North Wales. According to the terms of the agreement, the company retains production capacity to enable it serve various vaccines to the UK Government among them being AZD1222 which was co-invented by Oxford University and licensed by AstraZeneca.
Also Check Marksans Pharma Share Price Target
Manufacturing Capabilities
The Company has arrayed a multi-technology capacity which is all-encompassing in producing all forms of dose forms ranging from sterile injections to lyophilised products by establishing an inter-calibrated network of instruments. There are about 14 dynamically operating factories stationed in various countries across the world specifically in India, Britain and America with highly proficient craftsmen guiding them everyday and conforming to Food and Drug Administration standards of America, European Medicine Agency as well as British Medicine and Health Product Regulatory Agency.
Also Check Union Bank Share Price Target
Strategic Partnerships
Wockhardt Bio AG – a subsidiary of the Company and Jiangxi Jemincare Group Company Limited, China is in partnership with Wockhardt, the manufacturer of an innovative antibiotic named Nafithromycin to which the latter holds a patent. In turn, a global vaccine programme (~ 150 mn doses annually) between companies CP Pharmaceuticals Limited (a subsidiary of the Company) and Serum Life Sciences UK has been initiated.
Also Check Mazagon Dock Share Price Target
WOCKPHARMA Hospitals
There are 6 super-speciality hospitals owned by Wockhardt Hospitals in different parts of Gujarat and Maharashtra state. The hospital has pioneered in clinical excellence by high-quality healthcare provision and innovative research in regenerative medicine field touching on Stem Cells and Growth Factor Concentrate (GFC) Therapy in Hair Regrowth, Aesthetics, Orthopaedics, and Chronic Wound Healing.
Also check South Indian Bank Share Price Target
| Terms | Value |
|---|---|
| Market Cap | ₹ 8,238 Cr. |
| Current Price | ₹ 537 |
| High / Low | ₹ 630 / 167 |
| Stock P/E | |
| Book Value | ₹ 219 |
| Dividend Yield | 0.00 % |
| ROCE | -1.70 % |
| ROE | -13.4 % |
| Face Value | ₹ 5.00 |
| Debt to equity | 0.70 |
| Debt Capacity | -0.14 |
| Debt preceding year | ₹ 2,184 Cr. |
| Debt | ₹ 2,356 Cr. |
| Reserves | ₹ 3,282 Cr. |
| EPS | ₹ -30.2 |
| EPS last year | ₹ -30.2 |
| Pledged percentage | 52.9 % |
| FCF Prev Ann | ₹ 23.0 Cr. |
| EVEBITDA | 82.5 |
| Industry PE | 30.7 |
| PEG Ratio | |
| Piotroski score | 3.00 |
| Earnings yield | -1.01 % |
| Sales growth 5Years | -4.73 % |
Also Check L&T Finance Share Price Target
Wockhardt Quarterly Results
| Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 854 | 655 | 595 | 679 | 699 | 678 | 644 | 753 | 701 | 700 |
| Expenses + | 742 | 688 | 611 | 636 | 654 | 675 | 628 | 681 | 664 | 803 |
| Operating Profit | 112 | -33 | -16 | 43 | 45 | 3 | 16 | 72 | 37 | -103 |
| OPM % | 13% | -5% | -3% | 6% | 6% | 0% | 2% | 10% | 5% | -15% |
| Other Income + | 2 | -169 | 57 | -138 | -1 | -64 | 0 | 24 | 8 | 54 |
| Interest | 80 | 86 | 73 | 70 | 83 | 76 | 79 | 76 | 77 | 73 |
| Depreciation | 62 | 59 | 64 | 65 | 66 | 56 | 55 | 55 | 55 | 58 |
| Profit before tax | -28 | -347 | -96 | -230 | -105 | -193 | -118 | -35 | -87 | -180 |
| Tax % | 107% | 10% | 22% | 10% | 3% | -23% | -15% | -109% | 1% | 2% |
| Net Profit + | 2 | -311 | -75 | -207 | -102 | -237 | -136 | -73 | -86 | -177 |
| EPS in Rs | -0.49 | -17.91 | -4.65 | -13.12 | -6.66 | -14.44 | -9.30 | -5.34 | -5.76 | -11.02 |
ALso Check PCBL Share Price Target
WOCKPHARMA CAGR Report
| 10 Years | 5 Years | 3 Years | Last Year (TTM) | |
|---|---|---|---|---|
| Compounded Sales Growth | -5% | -5% | 1% | 6% |
| Compounded Profit Growth | -51% | |||
| Stock Price CAGR | 0% | 8% | -2% | 217% |
| Return on Equity | -1% | 0% | -8% | -13% |
Also Check Himadri Share Price Target
| Shareholder Type | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Promoters + | 74.25% | 74.11% | 74.07% | 72.13% | 72.12% | 67.13% | 59.31% | 51.60% |
| FIIs + | 4.55% | 5.45% | 4.74% | 4.85% | 3.10% | 2.89% | 2.78% | 5.49% |
| DIIs + | 2.71% | 4.99% | 2.55% | 0.24% | 0.09% | 0.09% | 0.22% | 4.82% |
| Government + | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% |
| Public + | 18.49% | 15.45% | 18.64% | 22.78% | 24.69% | 29.89% | 37.70% | 38.06% |
| No. of Shareholders | 1,24,403 | 99,736 | 1,14,338 | 1,17,324 | 1,25,488 | 1,72,460 | 1,82,493 | 1,46,138 |
| Year | Initial Target | Mid-Year Target | Year-End Target |
|---|---|---|---|
| 2024 | ₹529.44 | ₹660.8 | ₹739.61 |
| 2025 | ₹754 | ₹709 | ₹846 |
| 2026 | ₹863 | ₹811 | ₹968 |
| 2027 | ₹987 | ₹928 | ₹1108 |
| 2028 | ₹1130 | ₹1062 | ₹1267 |
| 2029 | ₹1292 | ₹1214 | ₹1450 |
| 2030 | ₹1479 | ₹1390 | ₹1660 |
| Month | Target |
| January | ₹754 |
| February | ₹769 |
| March | ₹784 |
| April | ₹758 |
| May | ₹733 |
| June | ₹709 |
| July | ₹737 |
| August | ₹766 |
| September | ₹797 |
| October | ₹813 |
| November | ₹829 |
| December | ₹846 |
| Month | Target |
| January | ₹863 |
| February | ₹880 |
| March | ₹898 |
| April | ₹868 |
| May | ₹839 |
| June | ₹811 |
| July | ₹843 |
| August | ₹877 |
| September | ₹912 |
| October | ₹930 |
| November | ₹949 |
| December | ₹968 |
| Month | Target |
| January | ₹987 |
| February | ₹1007 |
| March | ₹1027 |
| April | ₹993 |
| May | ₹960 |
| June | ₹928 |
| July | ₹965 |
| August | ₹1004 |
| September | ₹1044 |
| October | ₹1065 |
| November | ₹1086 |
| December | ₹1108 |
| Month | Target |
| January | ₹1130 |
| February | ₹1153 |
| March | ₹1176 |
| April | ₹1137 |
| May | ₹1099 |
| June | ₹1062 |
| July | ₹1104 |
| August | ₹1148 |
| September | ₹1194 |
| October | ₹1218 |
| November | ₹1242 |
| December | ₹1267 |
| Month | Target |
| January | ₹1292 |
| February | ₹1318 |
| March | ₹1344 |
| April | ₹1299 |
| May | ₹1256 |
| June | ₹1214 |
| July | ₹1263 |
| August | ₹1314 |
| September | ₹1367 |
| October | ₹1394 |
| November | ₹1422 |
| December | ₹1450 |
| Month | Target |
| January | ₹1479 |
| February | ₹1509 |
| March | ₹1539 |
| April | ₹1488 |
| May | ₹1438 |
| June | ₹1390 |
| July | ₹1446 |
| August | ₹1504 |
| September | ₹1564 |
| October | ₹1595 |
| November | ₹1627 |
| December | ₹1660 |
Official Website –wockhardt.com